The Genetic Basis for Vulnerability to Substance Abuse

NCT00247819 | Completed

• 1 other identifier: NIDA-IRP-148
• Study Type: observational
• Target: 8,000
• Locations: 1 country
• Sites: 1

Brief Summary

This investigation seeks to better define the genetic basis for vulnerability to substance abuse.

Conditions

Substance Abuse

Keywords

Substance abuse

Interventions

Blood draw PROCEDURE

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Substance abusers
• Allow for blood draw

You may not qualify if:

• Cognitively impaired

Sponsors & Collaborators

• National Institute on Drug Abuse (NIDA): lead

Study Sites (1)

National Institute on Drug Abuse

Baltimore, Maryland, 21224, United States

Location

Related Publications (17)

• Noble EP, Blum K, Khalsa ME, Ritchie T, Montgomery A, Wood RC, Fitch RJ, Ozkaragoz T, Sheridan PJ, Anglin MD, et al. Allelic association of the D2 dopamine receptor gene with cocaine dependence. Drug Alcohol Depend. 1993 Oct;33(3):271-85. doi: 10.1016/0376-8716(93)90113-5.

  PMID: 8261891 BACKGROUND

• Clark CJ, Downie CC. A method for the rapid determination of the number of patients to include in a controlled clinical trial. Lancet. 1966 Dec 17;2(7477):1357-8. doi: 10.1016/s0140-6736(66)92098-8. No abstract available.

  PMID: 4162809 BACKGROUND

• Grandy DK, Litt M, Allen L, Bunzow JR, Marchionni M, Makam H, Reed L, Magenis RE, Civelli O. The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. Am J Hum Genet. 1989 Nov;45(5):778-85.

  PMID: 2573278 BACKGROUND

• Hill SY, Armstrong J, Steinhauer SR, Baughman T, Zubin J. Static ataxia as a psychobiological marker for alcoholism. Alcohol Clin Exp Res. 1987 Aug;11(4):345-8. doi: 10.1111/j.1530-0277.1987.tb01323.x.

  PMID: 3307504 BACKGROUND

• Shigeta Y, Ishii H, Takagi S, Yoshitake Y, Hirano T, Takata H, Kohno H, Tsuchiya M. HLA antigens as immunogenetic markers of alcoholism and alcoholic liver disease. Pharmacol Biochem Behav. 1980;13 Suppl 1:89-94. doi: 10.1016/s0091-3057(80)80014-1.

  PMID: 7243836 BACKGROUND

• Smith SS, O'Hara BF, Persico AM, Gorelick DA, Newlin DB, Vlahov D, Solomon L, Pickens R, Uhl GR. Genetic vulnerability to drug abuse. The D2 dopamine receptor Taq I B1 restriction fragment length polymorphism appears more frequently in polysubstance abusers. Arch Gen Psychiatry. 1992 Sep;49(9):723-7. doi: 10.1001/archpsyc.1992.01820090051009.

  PMID: 1355337 BACKGROUND

• Uhl GR, Liu QR, Walther D, Hess J, Naiman D. Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. Am J Hum Genet. 2001 Dec;69(6):1290-300. doi: 10.1086/324467. Epub 2001 Nov 6.

  PMID: 11704927 BACKGROUND

• Moolchan ET, Radzius A, Epstein DH, Uhl G, Gorelick DA, Cadet JL, Henningfield JE. The Fagerstrom Test for Nicotine Dependence and the Diagnostic Interview Schedule: do they diagnose the same smokers? Addict Behav. 2002 Jan-Feb;27(1):101-13. doi: 10.1016/s0306-4603(00)00171-4.

  PMID: 11800217 BACKGROUND

• Uhl GR, Liu QR, Naiman D. Substance abuse vulnerability loci: converging genome scanning data. Trends Genet. 2002 Aug;18(8):420-5. doi: 10.1016/s0168-9525(02)02719-1.

  PMID: 12142011 BACKGROUND

• Stein L, Belluzzi J. Second messengers, natural rewards, and drugs of abuse. Clin Neuropharmacol. 1986;9 Suppl 4:205-7. No abstract available.

  PMID: 3032425 BACKGROUND

• Uhl GR, Gold LH, Risch N. Genetic analyses of complex behavioral disorders. Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):2785-6. doi: 10.1073/pnas.94.7.2785. No abstract available.

  PMID: 9096294 BACKGROUND

• Uhl GR, Persico AM, Smith SS. Current excitement with D2 dopamine receptor gene alleles in substance abuse. Arch Gen Psychiatry. 1992 Feb;49(2):157-60. doi: 10.1001/archpsyc.1992.01820020068010. No abstract available.

  PMID: 1347991 BACKGROUND

• Johnson EO, van den Bree MB, Uhl GR, Pickens RW. Indicators of genetic and environmental influences in drug abusing individuals. Drug Alcohol Depend. 1996 May;41(1):17-23. doi: 10.1016/0376-8716(96)01223-9.

  PMID: 8793306 BACKGROUND

• Uhl GR. Molecular genetics of substance abuse vulnerability: a current approach. Neuropsychopharmacology. 1999 Jan;20(1):3-9. doi: 10.1016/S0893-133X(98)00061-X. No abstract available.

  PMID: 9885780 BACKGROUND

• Wise RA. Action of drugs of abuse on brain reward systems. Pharmacol Biochem Behav. 1980;13 Suppl 1:213-23. doi: 10.1016/s0091-3057(80)80033-5. No abstract available.

  PMID: 6113601 BACKGROUND

• Gelernter J, Moises H, Grandy D, et al. Exclusion of schizophrenia triat from regions of the D2 dopamine receptor and prophobilinogen deaminase genes. In: 28th Annual Meeting, American College of Neurophyschopharmacology, December 13, 1980; Maui, Hawaii, Abstracts p.216.

  BACKGROUND

• Wyatt RJ, Farouk K, Suddath R, Hitri A. The role of dopamine in cocaine use and abuse. Psychiatric Annals 1988; 18:531-534.

  BACKGROUND

MeSH Terms

Conditions

Substance-Related Disorders

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Chemically-Induced Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Study Officials

• George Uhl, M.D., Ph.D.

  National Institute on Drug Abuse (NIDA)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: NIH

Study Record Dates

• First Submitted: October 31, 2005
• First Posted: November 2, 2005
• Study Start: August 1, 1992
• Primary Completion: February 1, 2006
• Study Completion: February 1, 2006
• Last Updated: January 12, 2017

Record last verified: 2005-10

Locations

US (1)